Prince Pharmaceutical Co., Ltd.(TW:6935)
NT$28.00-0.20 (-0.71%)
TW:6935
Prince Pharmaceutical Co., Ltd. financials statements
NT$28.00
At close:-0.20 (-0.71%)
Prince Pharmaceutical Co., Ltd. (6935) Ratios
Prince Pharmaceutical Co., Ltd. Ratios
TW:6935's free cash flow for Q2 2026 was NT$94.54M. For the 2026 fiscal year, TW:6935's free cash flow was decreased by NT$-7.36M and operating cash flow was NT$101.90M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.81 | 1.56 | 1.85 | 1.59 | 1.37 |
| Quick Ratio | 1.15 | 0.95 | 1.10 | 0.80 | 0.74 |
| Cash Ratio | 0.49 | 0.44 | 0.58 | 0.38 | 0.36 |
| Solvency Ratio | 0.24 | 0.01 | 0.12 | 0.16 | 0.06 |
| Operating Cash Flow Ratio | 0.29 | 0.20 | 0.29 | 0.48 | 0.21 |
| Short-Term Operating Cash Flow Coverage | 1.43 | 0.74 | 1.01 | 1.49 | 0.55 |
| Net Current Asset Value | NT$ -103.92M | NT$ -261.06M | NT$ -245.08M | NT$ -344.23M | NT$ -412.48M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.34 | 0.35 | 0.40 | 0.44 |
| Debt-to-Equity Ratio | 0.50 | 0.64 | 0.63 | 0.79 | 0.94 |
| Debt-to-Capital Ratio | 0.33 | 0.39 | 0.39 | 0.44 | 0.48 |
| Long-Term Debt-to-Capital Ratio | 0.22 | 0.27 | 0.28 | 0.33 | 0.38 |
| Financial Leverage Ratio | 1.79 | 1.87 | 1.82 | 1.98 | 2.14 |
| Debt Service Coverage Ratio | 2.30 | 0.26 | 1.17 | 1.60 | 0.54 |
| Interest Coverage Ratio | 11.57 | -4.81 | 2.46 | 7.59 | -0.15 |
| Debt to Market Cap | 0.26 | 0.41 | 0.30 | 0.23 | 0.25 |
| Interest Debt Per Share | 11.78 | 12.89 | 14.07 | 16.03 | 17.28 |
| Net Debt to EBITDA | 1.53 | 17.31 | 4.17 | 3.59 | 11.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 21.07% | 10.76% | 20.32% | 28.88% | 28.45% |
| EBIT Margin | 10.82% | -6.06% | 3.93% | 10.26% | -0.62% |
| EBITDA Margin | 16.66% | 3.00% | 11.71% | 17.62% | 9.86% |
| Operating Profit Margin | 10.50% | -7.15% | 3.41% | 9.52% | -0.25% |
| Pretax Profit Margin | 9.92% | -7.55% | 2.54% | 9.01% | -2.34% |
| Net Profit Margin | 9.12% | -7.76% | 2.03% | 7.24% | -1.88% |
| Continuous Operations Profit Margin | 9.12% | -7.76% | 2.03% | 7.24% | -1.88% |
| Net Income Per EBT | 91.96% | 102.80% | 79.88% | 80.30% | 80.55% |
| EBT Per EBIT | 94.46% | 105.54% | 74.63% | 94.62% | 926.89% |
| Return on Assets (ROA) | 6.41% | -3.97% | 1.09% | 3.95% | -0.64% |
| Return on Equity (ROE) | 11.48% | -7.42% | 1.98% | 7.83% | -1.38% |
| Return on Capital Employed (ROCE) | 9.29% | -4.43% | 2.14% | 6.09% | -0.10% |
| Return on Invested Capital (ROIC) | 8.08% | -4.17% | 1.62% | 4.61% | -0.08% |
| Return on Tangible Assets | 6.41% | -3.97% | 1.09% | 3.96% | -0.64% |
| Earnings Yield | 8.45% | -6.69% | 1.26% | 2.99% | -0.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.36 | 5.92 | 6.93 | 9.81 | 7.06 |
| Payables Turnover | 5.38 | 5.70 | 7.08 | 9.15 | 4.61 |
| Inventory Turnover | 4.06 | 4.35 | 3.81 | 3.38 | 2.52 |
| Fixed Asset Turnover | 1.13 | 0.71 | 0.75 | 0.74 | 0.45 |
| Asset Turnover | 0.70 | 0.51 | 0.53 | 0.55 | 0.34 |
| Working Capital Turnover Ratio | 5.54 | 4.45 | 5.18 | 7.68 | 8.65 |
| Cash Conversion Cycle | 90.25 | 81.50 | 96.94 | 105.28 | 117.58 |
| Days of Sales Outstanding | 68.12 | 61.69 | 52.67 | 37.21 | 51.67 |
| Days of Inventory Outstanding | 90.00 | 83.86 | 95.86 | 107.94 | 145.08 |
| Days of Payables Outstanding | 67.87 | 64.05 | 51.59 | 39.88 | 79.18 |
| Operating Cycle | 158.13 | 145.56 | 148.53 | 145.16 | 196.75 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.46 | 1.26 | 1.76 | 2.76 | 1.28 |
| Free Cash Flow Per Share | 1.94 | 0.77 | 0.01 | 2.16 | 0.03 |
| Dividend Paid and CapEx Coverage Ratio | 4.79 | 1.70 | 0.92 | 4.63 | 1.03 |
| Capital Expenditure Coverage Ratio | 4.79 | 2.57 | 1.00 | 4.63 | 1.03 |
| Operating Cash Flow Coverage Ratio | 0.21 | 0.10 | 0.13 | 0.18 | 0.07 |
| Operating Cash Flow to Sales Ratio | 0.09 | 0.07 | 0.08 | 0.13 | 0.10 |
| Free Cash Flow Yield | 6.25% | 3.52% | 0.02% | 4.16% | 0.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.83 | -15.00 | 79.07 | 33.55 | -208.00 |
| Price-to-Sales (P/S) Ratio | 1.08 | 1.16 | 1.61 | 2.42 | 3.91 |
| Price-to-Book (P/B) Ratio | 1.36 | 1.11 | 1.56 | 2.62 | 2.86 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 16.00 | 28.38 | 4728.43 | 24.02 | 1598.18 |
| Price-to-Operating Cash Flow Ratio | 12.66 | 17.33 | 19.37 | 18.83 | 40.75 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | 0.03 | -1.09 | -0.05 | 2.75 |
| Enterprise Value Multiple | 8.01 | 56.03 | 17.90 | 17.34 | 51.06 |
| Enterprise Value | 1.41B | 1.16B | 1.58B | 2.18B | 2.22B |
| EV to EBITDA | 8.01 | 56.03 | 17.90 | 17.34 | 51.06 |
| EV to Sales | 1.33 | 1.68 | 2.10 | 3.06 | 5.03 |
| EV to Free Cash Flow | 19.78 | 41.07 | 6165.13 | 30.30 | 2055.12 |
| EV to Operating Cash Flow | 15.65 | 25.07 | 25.25 | 23.75 | 52.40 |
| Tangible Book Value Per Share | 22.87 | 19.74 | 21.72 | 19.79 | 18.10 |
| Shareholders’ Equity Per Share | 22.88 | 19.75 | 21.75 | 19.83 | 18.16 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | -0.03 | 0.20 | 0.20 | 0.19 |
| Revenue Per Share | 28.82 | 18.88 | 21.16 | 21.47 | 13.29 |
| Net Income Per Share | 2.63 | -1.46 | 0.43 | 1.55 | -0.25 |
| Tax Burden | 0.92 | 1.03 | 0.80 | 0.80 | 0.81 |
| Interest Burden | 0.92 | 1.25 | 0.65 | 0.88 | 3.74 |
| Research & Development to Revenue | 0.03 | 0.07 | 0.07 | 0.10 | 0.18 |
| SG&A to Revenue | 0.07 | 0.11 | 0.10 | 0.09 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Income Quality | 0.86 | -0.89 | 3.26 | 1.78 | -5.10 |
Currency in TWD
